Henni-Karoliina Ropponen, PhD MChem

Henni-Karoliina is a Venture Associate at the AMR Action Fund (AMRAF), the world’s largest venture capital fund focused on investing in antibiotics, antifungals, and related antimicrobial technologies. Since joining the Fund in 2023, she has been evaluating investment opportunities and supporting AMRAF’s growing number of portfolio companies in a multitude of ways, including serving on the board of directors of BioVersys AG and serving as a board observer for Utility Therapeutics and Elion Therapeutics.

Prior to joining AMRAF, she worked for the Global Antibiotic R&D Partnership, Roche, and the Helmholtz Institute for Pharmaceutical Research Saarland. She holds a Master of Chemistry with Drug Discovery from the University of Strathclyde, UK and a doctoral degree in natural sciences specialising in antibiotics and medicinal chemistry from Saarland University, Germany.